Evidence map›Paper›PMID 38854362›Full record

ArticleCureus2024

Personalizing Deep Brain Stimulation Therapy for Parkinson's Disease With Whole-Brain MRI Radiomics and Machine Learning.

Nikolaos Haliasos, Dimitrios Giakoumettis, Prathishta Gnanaratnasingham, Hu Liang Low, Anjum Misbahuddin, Panagiotis Zikos, Vangelis Sakkalis, Spanaki Cleo, Antonios Vakis, Sotirios Bisdas

Erratum issuedAbstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Nikolaos HaliasosNeurosurgery, Queen's Hospital, Romford, GBR.
Dimitrios GiakoumettisNeurosurgery, KAT General Athens Hospital, Athens, GRC.
Prathishta GnanaratnasinghamCentre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University, London, GBR.
Hu Liang LowNeurosurgery, Queen's Hospital, London, GBR.
Anjum MisbahuddinNeurology, Queen's Hospital, Romford, GBR.
Panagiotis ZikosNeurology, Metropolitan Hospital, Athens, GRC.
Vangelis SakkalisInstitute of Computer Science, Foundation for Research and Technology, Heraklion, GRC.
Spanaki CleoNeurology, School of Medicine, University of Crete, Heraklion, GRC.
Antonios VakisNeurosurgery, School of Medicine, University of Crete, Heraklion, GRC.
Sotirios BisdasNeuroradiology, University College London, London, GBR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Deep brain stimulation (DBS) is a well-recognised treatment for advanced Parkinson's disease (PD) patients. Structural brain alterations of the white matter can correlate with disease progression and act as a biomarker for DBS therapy outcomes. This study aims to develop a machine learning-driven predictive model for DBS patient selection using whole-brain white matter radiomics and common clinical variables. Methodology A total of 120 PD patients underwent DBS of the subthalamic nucleus. Their therapy effect was assessed at the one-year follow-up with the Unified Parkinson's Disease Rating Scale-part III (UPDRSIII) motor component. Radiomics analysis of whole-brain white matter was performed with PyRadiomics. The following machine learning methods were used: logistic regression (LR), support vector machine, naïve Bayes, K-nearest neighbours, and random forest (RF) to allow prediction of clinically meaningful UPRDSIII motor response before and after. Clinical variables were also added to the model to improve accuracy. Results The RF model showed the best performance on the final whole dataset with an area under the curve (AUC) of 0.99, accuracy of 0.95, sensitivity of 0.93, and specificity of 0.97. At the same time, the LR model showed an AUC of 0.93, accuracy of 0.88, sensitivity of 0.84, and specificity of 0.91. Conclusions Machine learning models can be used in clinical decision support tools which can deliver true personalised therapy recommendations for PD patients. Clinicians and engineers should choose between best-performing, less interpretable models vs. most interpretable, lesser-performing models. Larger clinical trials would allow to build trust among clinicians and patients to widely use these AI tools in the future.

Indexed as

artificial intelligencedeep brain stimulationinterpretabilitymachine learningparkinson’s diseaseradiomics

Identifiers

PMID38854362
PMCPMC11161197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.